CTOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

Perimeter Solutions

Perimeter Solutions is a global specialty chemicals company based in Clayton, Missouri, established in 1963. The company focuses on two main areas: fire safety solutions and lubricant additives. It is a market leader in both sectors, particularly known for its wildfire retardants, firefighting foams, and industrial fire suppressants. Perimeter Solutions offers a range of products, including water-enhancing gels and preventative fire retardants, catering to government agencies, municipalities, and industrial clients worldwide. In addition to fire safety, Perimeter Solutions specializes in niche engine oil additives, holding a significant market share in this area. These additives improve lubricant performance for both automotive and industrial applications. The company is publicly traded under the ticker PRM and is co-founded by Nick Howley, who also chairs the company. With a strong emphasis on innovation and a robust manufacturing and distribution network, Perimeter Solutions positions itself as a premier provider of chemical solutions in its industries.

Elements Room

Elements Room specializes in slab materials from all over the world both man-made and natural. Elements Room aims to be the first and single point of contact for premium surfaces throughout any project. The curated inventory features only the highest quality, trending surfaces. Created as a destination for designers, architects, and industry professionals looking to meet with clients outside of their home or office, the space provides the perfect combination of premium surface materials with comfortable, private work spaces and facilities. Superior materials on display include all types of natural stones, semi-precious, quartz and porcelain options.

DistroKid

DistroKid is a digital music distribution service based in the United States, founded in 2013 by Philip Kaplan. It emerged from a social media platform for musicians called Fandalism. DistroKid specializes in helping independent artists and labels distribute their music to major online retailers, including Spotify, Apple Music, Amazon Music, and YouTube Music. The company offers a range of services to support musicians, including music distribution, monetization of sales and streams, and metadata customization. DistroKid also provides storage solutions for music files and additional features like customized YouTube URLs and Digital Object Identifiers (DOIs). With a competitive pricing model, artists can upload unlimited songs and albums for an annual fee, while retaining 100% of their earnings. DistroKid has been utilized by various notable artists, showcasing its effectiveness in the DIY music distribution space.

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.